The effect of a series of antisense oligodeoxyribonucleotides [oligo(dN)] on the expression of the surface antigen (HBsAg) gene of human hepatitis B virus (HBV) was examined using hepatocellular carcinoma cells that contain integrated HBV genomes. Of a number of antisense oligo(dN)s tested, synthetic 15-mers directed at the cap site of mRNA and regions of the translational initiation site of the HBsAg gene were found to be highly effective and inhibited viral gene expression by as much as 96 %. The inhibition was specific to the HBsAg gene and appeared to be at the level of translation. These results suggest a therapeutic potential for antisense oligo(dN) in the treatment of patients who are chronically infected with HBV.
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Hepatitis B virus (HBV) is a small enveloped DNA virus belonging to the hepadnavirus family (Tiollais et al., 1985) . HBV infection has a wide range of clinical manifestations, which include severe complications such as fulminant hepatitis, chronic hepatitis and cirrhosis (Hollinger et al., 1985) . Approximately 300 million carriers of the virus world-wide are at serious risk of chronic liver diseases (Ganem, 1982; Szmuness, 1988) . Moreover, epidemiological studies suggest the close association of chronic HBV infection with primary hepatocellular carcinoma (HCC) (Beasley et al., 1981; Maupas & Melnick, 1981) . Recently it has also been suggested that HBV might be a cofactor in the development of acquired immune deficiency syndrome (Quinn et al., 1987) becasue the gene X protein of HBV has been shown to be a trans-activator of human immunodeficiency virus genes (Seto et al., 1988; Twu & Robinson, 1989) . At present, vaccination for HBV is the sole protective measure available against HBV infection. However, the search for a therapeutic agent that can effectively inhibit HBV infection of the millions of people who become infected each year has remained open.
Recently, there has been a growing interest in the potential application of antisense oligodeoxyribonucleotides [oligo(dN)] in the inhibition of gene expression and, hence, as a possible treatment for viral infection (Zamecnik et al., 1986; Goodchild et al., 1988; . We have studied the inhibitory effect of antisense oligo(dN)s directed against various regions of the HBV genome on the expression of the HBV surface antigen (HBsAg) using a tissue cell line derived from a patient with HCC. This cell line, PLC/PRF/5 (from the American type Culture Collection), contains several copies of integrated HBV DNA (Rivkina et al., 1988) and the cells express and secrete HBsAg which is immunochemically identical to that isolated from human plasma .
Initially, we chose five target sites for antisense oligo(dN) in the region of the pre-S and S genes of the HBV genome and synthesized 12-to 15-mers of oligo(dN)s complementary to their mRNA. These sites included the cap site of mRNA transcribed from the SPII promoter (cap site/SPII), a region inside the pre-S2 gene (inside/pre-S2), the translation initiation site of the S gene (initiator/gene S), a region about 10 bases downstream of the initiation site of the S gene (inside I/gene S) and a region around the middle of the S gene (inside II/gene S). As a control, two oligo(dN)s with random sequences were also synthesized; one was a 15-mer (non-complementary I) and the other was a 12-mer (non-complementary II). Briefly, PLC/PRF/5 cells were grown in MEM containing 10% foetal bovine serum in a micro-culture plate at 37 °C. Each well was washed three times with phosphate-buffered saline (PBS) and MEM was added. Antisense oligo(dN) was added at 0 h and 24 h to a final concentration of 17.4 p.M. Culture supernatant (20 ~tl) was taken after 72 h incubation at 37 °C in 7-5 % CO2, diluted to 200 ~tl in PBS and HBsAg levels were measured with an Abbot Auszyme leit. Assays, performed in duplicate, allowed the inhibitory effects of antisense oligo(dN) on the expression of HBsAg to be examined. As shown in Table 1 , the degree of inhibition by a series of oligo(dN)s varied depending on the target Ono et al. (1983) . t NA, Not applicable. site. In particular, antisense oligo(dN)s directed against the cap site/SPII, inside/pre-S2, initiator/gene S and inside I/gene S showed a similar and high degree of inhibition of as much as 96%. In sharp contrast, the antisense oligo(dN) directed against the inside II/gene S showed essentially no inhibitory effect. Both control oligo(dN)s, non-complementary I and II, had little effect on the expression of HBsAg. These results suggest that the inhibitory effect of antisense oligo(dN) is sequencespecific and that those directed against the cap site and the region around the initiation site, either upstream or downstream, are most effective in inhibiting gene expression. Our results are consistent with the previous notion that antisense oligo(dN)s are, in general, most effective when directed against the translational initiation site . Therefore we chose this site for the following experiments. In order to examine the specificity of the inhibitory effect of the antisense oligo(dN)s on the HBsAg gene, the amount of transferrin in the medium and total protein synthesis were assayed in the presence or absence of antisense oligo(dN) directed against the initiator/gene S. Initiator/S gene oligo(dN) (17-4 p.M) was added to the medium of PLC/PRF/5 cells and after 120 h incubation medium was withdrawn and assayed for HBsAg.
Transferrin is one of the plasma proteins secreted into the tissue culture medium of PLC/PRF/5 cells (Knowles et al., 1980) . The amount of transferrin was measured by ELISA using polyclonal antibody raised against purified human transferrin, which was used as a standard. Total protein synthesis was assayed by measuring the incorporation of a 35S-labelled amino acid mixture (incubated at 10 ~tCi/ml, 15 min, 37 °C) into tissue cells (the incorporation of acid-insoluble radioisotopes into cells was measured). As shown in Table 2 , the addition of the antisense oligo(dN) had little effect on either the expression of transferrin or total cellular protein synthesis; however the same antisense oligo(dN) inhibited 95 of HBsAg expression. These results, as well as the results of sequence-specific inhibition of HBsAg shown in Table  1 , imply that the inhibitory effect of the antisense oligo(dN) is indeed specific to the target gene.
In an attempt to understand the mechanism of action of the antisense oligo(dN), we performed a dot-blot analysis of HBsAg RNA in the presence of various antisense oligo(dN)s. PLC/PRF/5 cells were grown and incubated for 60 h with or without antisense oligo(dN)s. RNAs were extracted, blotted and hydridized as described (Chomczynski & Sacchi, 1987; Sambrook et al., 1989 ) with a 32p-labelled probe for the HBsAg gene. The probe DNA was a 32p-labelled BamHI fragment of plasmid pAM6 (Moriarty et al., 1981) , which contains the entire HBsAg gene. After autoradiography, the probe was stripped off the membrane which was then rehybridized with a fl-tublin DNA probe in order to normalize the results of hybridization. Each spot on the autoradiograph film was measured by a densitometer. As shown in Fig. l , the amount of RNA did not significantly change in the presence of a series of antisense oligo(dN)s. It is generally believed that an antisense oligo(dN) hybridizes to its mRNA target sequence and inhibits translation by blocking the binding or movement of translation factors and rRNA, or by degrading the DNA/RNA hybrid with RNase H (Walder & Walder, 1988) . Our results are consistent with the above hypothesis and suggest that the inhibition of HBsAg expression by the antisense oligo(dN) appears to be at the level of translation and not at that of transcription. This is further supported by the evidence that antisense oligo(dN) was most effective when directed against the region of the initiation site of the S gene, whereas it was least effective when directed against the inside II/gene S (Table l) . Using the antisense oligo(dN) directed against the initiator/gene S, the duration of the inhibitory effect was examined. The 15-mer oligo(dN) was administered at time 0 and at 24 h, to a final concentration of 17-4 ~tM, and the expression of HBsAg was subsequently assayed at 24h intervals. As shown in Fig. 2 , the antisense oligo(dN) remained effective in inhibiting the expression of HBsAg for at least 120 h after the second administration of the antisense oligo(dN); the inhibitory effect gradually diminished after 120 h. The cells remained viable throughout the experiment and no morphological abnormalities were observed. Table 3 shows the effects of the addition of multiple doses of antisense oligo(dN) complementary to the initiator/gene S. A single dose, at a concentration of 17.4 ~M, resulted in up to 92~o inhibition of HBsAg expression and was as effective as the same total amount of material administered in two separate doses. However, multiple doses at a lower concentration (2.9 pM) over a period of 4 days, equivalent to a total final concentration of 11.6 ~M, where not as effective as the administration of a single dose at a total concentration of 8.7 r~M. Therefore, the initial concentration of antisense oligo(dN) appears to be an important factor in obtaining the optimum inhibitory effect. We also examined the effect of a phosphorothioate analogue of the oligomers (S-oligo), because S-oligo is known to be more resistant to nuclease, and has a higher efficiency of cellular uptake, than oligo(dN) (Macnab et al., 1976; Eckstein, 1985; Matsukura et al., 1988) . As shown in Table 4 , increasing amounts of oligo(dN) directed against the initiator/gene S, with final concentrations ranging from 0.58 ~tM to 17"4p.M, resulted in increased inhibition of the expression of HBsAg. At similar concentrations, S-oligo of the same length and sequence as the oligo(dN) had a greater inhibitory effect. This was particularly apparent at low concentrations of the oligomers.
In the case of patients with HBV infection, it has been suggested that expression of HBsAg on the surface of liver cells, through its interaction with the host's cellular immune system, plays a key role in the pathogenesis of liver damage (Hollinger et al., 1985) . It is also known that HBsAg circulating in the blood forms immune complexes with immunoglobulin which then cause a variety of clinical symptoms (Hollinger et al., 1985) . Furthermore, it has been recently demonstrated that the HBsAg expression level has a clear correlation with liver cell injury and the development of HCC in transgenic mice which carry the HBsAg gene (Chisari et al., 1989) . Therefore, it is anticipated that inhibition of HBsAg expression could significantly reduce the risk of complications for patients with HBV infection. Although the experiments presented here have been carried out with cells in culture, our results suggest that antisense oligo(dN) can inhibit HBsAg expressed from the integrated HBV genome and hence have a therapeutic potential for the treatment of patients chronically infected with HBV. We believe that the unique system described here may provide a useful method for designing an effective antisense oligo(dN) for the regulation of HBV gene expression.
